Literature DB >> 21233253

Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine.

Sami F Noujaim1, Jeanne A Stuckey, Daniela Ponce-Balbuena, Tania Ferrer-Villada, Angelica López-Izquierdo, Sandeep V Pandit, José A Sánchez-Chapula, José Jalife.   

Abstract

AIMS: Chloroquine, an anti-malarial quinoline, is structurally similar to quinidine. Both drugs have been shown to block ion channels. We tested the hypothesis that chloroquine's mode of interaction with the vestibule of the cytoplasmic domain of the inward rectifier potassium channel Kir2.1 makes it a more effective I(K1) blocker and anti-fibrillatory agent than quinidine. METHODS AND
RESULTS: We used comparative molecular modelling and ligand docking of the three-dimensional structures of quinidine and chloroquine in the intracellular domain of Kir2.1. Simulations predicted that chloroquine effectively blocks potassium flow by binding at the centre of the ion permeation vestibule of Kir2.1. In contrast, quinidine binds the vestibular side, only partially blocking ion movement. We tested the modelling predictions in Kir2.1-expressing human embryonic kidney (HEK)-293 cells. The half-maximal inhibitory concentration for chloroquine block of I(K1) was 1.2 µM, while that of quinidine was 57 µM. Finally, we used optical mapping of Langendorff-perfused mouse hearts with cardiac-specific Kir2.1 up-regulation to compare the anti-fibrillatory effects of the drugs. In five of six hearts, 10 μM quinidine slowed the frequency but did not terminate the tachyarrhythmia. In five of five hearts, 10 μM chloroquine terminated the arrhythmia, restoring sinus rhythm.
CONCLUSION: Quinidine only partially blocks I(K1). Chloroquine binds at the centre of the ion permeation vestibule of Kir2.1, which makes it a more effective I(K1) blocker and anti-fibrillatory agent than quinidine. Integrating the structural biology of drug-ion channel interactions with cellular electrophysiology and optical mapping is an excellent approach to understand the molecular mechanisms of anti-arrhythmic drug action and for drug discovery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233253      PMCID: PMC3039250          DOI: 10.1093/cvr/cvr008

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  28 in total

1.  Chloroquine and hydroxychloroquine in the treatment of cardiac arrhythmias.

Authors:  Z L BURRELL; A C MARTINEZ
Journal:  N Engl J Med       Date:  1958-04-17       Impact factor: 91.245

Review 2.  Molecular physiology of cardiac repolarization.

Authors:  Jeanne M Nerbonne; Robert S Kass
Journal:  Physiol Rev       Date:  2005-10       Impact factor: 37.312

3.  Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites for modulating gating and rectification.

Authors:  Scott Pegan; Christine Arrabit; Wei Zhou; Witek Kwiatkowski; Anthony Collins; Paul A Slesinger; Senyon Choe
Journal:  Nat Neurosci       Date:  2005-02-20       Impact factor: 24.884

4.  A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation.

Authors:  Min Xia; Qingfeng Jin; Saïd Bendahhou; Yusong He; Marie-Madeleine Larroque; Yiping Chen; Qinshu Zhou; Yiqing Yang; Yi Liu; Ban Liu; Qian Zhu; Yanting Zhou; Jie Lin; Bo Liang; Li Li; Xiongjian Dong; Zhiwen Pan; Rongrong Wang; Haiying Wan; Weiqin Qiu; Wenyuan Xu; Petra Eurlings; Jacques Barhanin; Yihan Chen
Journal:  Biochem Biophys Res Commun       Date:  2005-07-15       Impact factor: 3.575

5.  Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.

Authors:  Christian Wolpert; Rainer Schimpf; Carla Giustetto; Charles Antzelevitch; Jonathan Cordeiro; Robert Dumaine; Ramon Brugada; Kui Hong; Urs Bauersfeld; Fiorenzo Gaita; Martin Borggrefe
Journal:  J Cardiovasc Electrophysiol       Date:  2005-01

6.  Reentry and fibrillation in the mouse heart. A challenge to the critical mass hypothesis.

Authors:  D Vaidya; G E Morley; F H Samie; J Jalife
Journal:  Circ Res       Date:  1999-07-23       Impact factor: 17.367

7.  Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype.

Authors:  Li Zhang; D Woodrow Benson; Martin Tristani-Firouzi; Louis J Ptacek; Rabi Tawil; Peter J Schwartz; Alfred L George; Minoru Horie; Gregor Andelfinger; Gregory L Snow; Ying-Hui Fu; Michael J Ackerman; G Michael Vincent
Journal:  Circulation       Date:  2005-05-23       Impact factor: 29.690

8.  Up-regulation of the inward rectifier K+ current (I K1) in the mouse heart accelerates and stabilizes rotors.

Authors:  Sami F Noujaim; Sandeep V Pandit; Omer Berenfeld; Karen Vikstrom; Marina Cerrone; Sergey Mironov; Michelle Zugermayr; Anatoli N Lopatin; José Jalife
Journal:  J Physiol       Date:  2006-11-09       Impact factor: 5.182

9.  Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.

Authors:  Peter Milberg; Regina Tegelkamp; Nani Osada; Rainer Schimpf; Christian Wolpert; Günter Breithardt; Martin Borggrefe; Lars Eckardt
Journal:  J Cardiovasc Electrophysiol       Date:  2007-06

10.  A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene.

Authors:  Silvia G Priori; Sandeep V Pandit; Ilaria Rivolta; Omer Berenfeld; Elena Ronchetti; Amit Dhamoon; Carlo Napolitano; Justus Anumonwo; Marina Raffaele di Barletta; Smitha Gudapakkam; Giuliano Bosi; Marco Stramba-Badiale; José Jalife
Journal:  Circ Res       Date:  2005-03-10       Impact factor: 17.367

View more
  24 in total

Review 1.  Cardiac ion channels.

Authors:  Birgit T Priest; Jeff S McDermott
Journal:  Channels (Austin)       Date:  2015-08-20       Impact factor: 2.581

2.  Gold nanoparticle-spermidine complex blocks the inward rectifier potassium channel.

Authors:  Chur Chin
Journal:  Am J Cardiovasc Dis       Date:  2014-06-28

3.  Styrax blocks inward and outward current of Kir2.1 channel.

Authors:  Shuxi Ren; Chunli Pang; Junwei Li; Yayue Huang; Suhua Zhang; Yong Zhan; Hailong An
Journal:  Channels (Austin)       Date:  2016-08-12       Impact factor: 2.581

4.  Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule.

Authors:  Yoshio Takemoto; Diana P Slough; Gretchen Meinke; Christopher Katnik; Zachary A Graziano; Bojjibabu Chidipi; Michelle Reiser; Mohammed M Alhadidy; Rafael Ramirez; Oscar Salvador-Montañés; Steven Ennis; Guadalupe Guerrero-Serna; Marian Haburcak; Carl Diehl; Javier Cuevas; Jose Jalife; Andrew Bohm; Yu-Shan Lin; Sami F Noujaim
Journal:  FASEB J       Date:  2018-01-05       Impact factor: 5.191

5.  Inward rectifying potassium currents resolved into components: modeling of complex drug actions.

Authors:  Jiří Šimurda; Milena Šimurdová; Markéta Bébarová
Journal:  Pflugers Arch       Date:  2017-09-26       Impact factor: 3.657

6.  Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224.

Authors:  Panagiotis Xynogalos; Claudia Seyler; Daniel Scherer; Christoph Koepple; Eberhard P Scholz; Dierk Thomas; Hugo A Katus; Edgar Zitron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-04       Impact factor: 3.000

Review 7.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 8.  Novel molecular targets for atrial fibrillation therapy.

Authors:  Dobromir Dobrev; Leif Carlsson; Stanley Nattel
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

Review 9.  Rotors and the dynamics of cardiac fibrillation.

Authors:  Sandeep V Pandit; José Jalife
Journal:  Circ Res       Date:  2013-03-01       Impact factor: 17.367

10.  KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia.

Authors:  Makarand Deo; Yanfei Ruan; Sandeep V Pandit; Kushal Shah; Omer Berenfeld; Andrew Blaufox; Marina Cerrone; Sami F Noujaim; Marco Denegri; José Jalife; Silvia G Priori
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.